US Supreme Court Declines To Hear 280E Marijuana Tax Case

Marijuana businesses hoping to see the end of onerous 280E tax provisions were dealt a setback by the nation’s highest court.

The U.S. Supreme Court declined to review a petition brought by a Colorado medical cannabis dispensary challenging the authority of the Internal Revenue Service.

Alpenglow Botanicals, based in Breckenridge, argued in its petition to the high court that Section 280E of the federal tax code doesn’t empower the IRS to investigate and rule that a marijuana business has violated federal criminal drug laws.

The federal government responded that 280E specifies that no tax deduction or credit should be allowed for any expense paid or incurred in carrying out a business that “consists of trafficking in controlled substances.”

Marijuana is listed as a Schedule 1 drug under the Controlled Substances Act.

Both the U.S. District Court in Colorado and the 10th Circuit Court of Appeals in Denver had affirmed the IRS ruling.

Alpenglow had claimed a variety of business deductions that the IRS determined were prohibited by 280E.

The denial of the deductions resulted in Alpenglow owners Charles and Justin Williams owing a total of $53,094 to the IRS, according to court documents.

After the bill was paid, Alpenglow filed refund claims and started on the road of challenging in court the application of 280E.

Alpenglow’s attorney didn’t immediately respond to Marijuana Business Daily‘s request for comment.

Jeff Smith can be reached at [email protected]

Original Article Source: https://mjbizdaily.com/us-supreme-court-declines-to-hear-280e-marijuana-tax-case/

Comments

New York City Adds More Exceptions To Pre-Employment Marijuana Testing Ban

An ambitious campaign to decriminalize psychedelics in Washington, D.C., is one step closer to placing their measure on the November ballot with the formal submission of tens of thousands of voter signatures. Organizers have been scrambling for weeks to collect enough signatures from D.C. voters by Monday’s deadline amid historically difficult circumstances: a global pandemic, months of stay-at-home orders and protests over racism and police violence that filled the streets of the nation’s capital. But with the help of innovative signature-gathering techniques and allies flown in from across the country, advocates said they had successfully submitted upwards of 35,000 signatures—more than enough to qualify the initiative. If approved by voters, Initiative 81 would make enforcement of laws against plant- and fungus-based psychedelics among the “lowest law enforcement priorities” for the Metropolitan Police Department. It would not, however, legalize or reduce penalties for the subs

Charlotte Figi The Girl Who Inspired A CBD Movement Has Died At Age 13

Charlotte had recently been hospitalized due to pneumonia, breathing problems and seizures. She was treated as a likely case of Covid-19, her mother, Paige Figi, said Wednesday, although she tested negative for the virus. “Charlotte is no longer suffering. She is seizure-free forever,” a family friend wrote on Paige Figi’s Facebook page, announcing Charlotte’s death. “Thank you so much for all of your love.” Charlotte became a symbol of the possibilities of CBD after CNN Chief Medical Correspondent Dr. Sanjay Gupta told her story in the documentary “Weed.” In the film, Charlotte was shown to be a playful child who was overcome by horrific seizures, which were quelled with Charlotte’s Web, a marijuana strain named in her honor. Charlotte had Dravet syndrome, a rare form of epilepsy which was not controlled by medication. The Stanley brothers, marijuana growers in Colorado, were crossbreeding a strain of marijuana high in CBD and low in THC, its psychoactive ingredient. After Charlo

Virginia CBD Program Criticized As Multistate Medical Cannabis Operators Gain Edge

Seven companies are challenging a CBD licensing process in Virginia that resulted in multistate medical marijuana operators getting a majority of available licenses. The appeals called the process “wildly prejudicial.” Out of 51 applicants for five vertically integrated CBD and THC-A licenses, multistate operators received three, a situation that spurred the appeals, The Virginian-Pilot reported. Applicants filing the appeals complained the closed-meeting review process lacked fairness and transparency. One consultant to an applicant said the selections felt “predetermined.” The Virginia Board of Pharmacy reportedly sent information to the applicants in December explaining its selections, but some applicants weren’t satisfied. A board spokeswoman wrote in an email to the Pilot that the board “does not comment on pending litigation.” The five winning applicants , called “pharmaceutical processors,” have a year from winning the licenses to become operational. The multistate

Susan Duggan

Search This Blog